GLOW peptide before and after: what the evidence shows

The short answer: there are no controlled GLOW peptide before and after results. GLOW is a nickname for an injectable mix of three peptides, GHK-Cu, BPC-157, and TB-500, and no published study has tested the combination in people or in animals. [15] The photos online are not evidence, for reasons that have nothing to do with whether the people in them are honest. The closest measured human outcomes come from small studies of topical GHK-Cu creams, which is a different route from the one in a GLOW vial. [1]

This post covers what GLOW is, what human evidence exists for each ingredient on skin and hair, why before and after photos mislead, what side effects are documented, and where the blend stands legally. It does not give doses or instructions, and it does not recommend GLOW or any peptide.

What is GLOW peptide?

GLOW is usually sold as one vial containing GHK-Cu, BPC-157, and TB-500, marketed for skin, hair, and healing. The ratio and total amount differ from product to product, some labels add other ingredients, and research-chemical products are not made or tested to a drug standard, so what a vial contains is not verified.

Each ingredient is assigned a job in the marketing:

• GHK-Cu is the skin, collagen, and hair component, based mainly on topical cosmetic studies. [1]
• BPC-157 is the tissue healing component, based on rodent studies. [7]
• TB-500 is the recovery and wound repair component, based on animal studies of full-length thymosin beta-4, which FDA says is not the same substance as TB-500. [16]

A related blend, KLOW, adds a fourth peptide, KPV. We compare the two in Klow vs Glow.

What human evidence exists for GLOW's skin and hair benefits?

Because the blend itself has never been tested, the only way to judge the claimed benefits is ingredient by ingredient. Here is the controlled human evidence for each one on skin and hair outcomes.

GHK-Cu on skin. This is the ingredient with real human data, and all of it is topical. Reviews describe small controlled cosmetic studies in which copper peptide creams tightened loose skin, improved elasticity and density, and reduced fine lines over weeks of daily use. [1] Those studies are small, mostly industry associated, and summarized in reviews written largely by the peptide's discoverer. [1] The one indexed randomized trial, of copper peptide skin care after laser resurfacing with 13 patients completing it, found no difference in redness, wrinkles, or overall skin quality on blinded and computer assessment, although patients using it rated their skin higher. [3] A lab study also showed that copper from a topical GHK-Cu solution can pass into human skin, which undercuts the claim that injection is the only way to reach skin cells. [4] We compare the two routes in topical vs injectable GHK-Cu, and the skin aging page covers options with stronger evidence.

GHK-Cu on hair. Copper peptide complexes enlarged hair follicles in mice. [5] The one controlled human hair trial involving GHK tested it in a complex with 5-aminolevulinic acid in 45 men: hair count rose more than with placebo, with no difference in hair length or thickness. [6] Because GHK was paired with another active ingredient, that trial cannot show what GHK-Cu does alone. Details are in copper peptides for hair and on the hair loss page.

BPC-157. A 2025 systematic review found 35 preclinical studies and one small retrospective human report, none on skin or hair. [7] A narrative review the same year described the human data as extremely limited. [8]

TB-500. FDA's July 2026 briefing found no article in which TB-500 was given to humans. [16] The skin ulcer trial often quoted for it tested topical full-length thymosin beta-4, a 43 amino acid protein, not the 7 amino acid TB-500 fragment. [13]

Put together: no human study has measured skin, hair, or healing outcomes after injecting GLOW or any of its three peptides.

Why are GLOW before and after photos not evidence?

A before and after photo answers one question: did this person look different later? It cannot answer the question that matters: did the product cause the difference? Several things change between two photos that have nothing to do with a vial:

• Lighting and camera. Light angle, color temperature, distance, lens, and filters can soften lines and even out tone on their own.
• Other treatments. People who buy a skin blend often also start retinoids, sunscreen, facials, or laser treatments, and change sleep, hydration, or weight.
• No control group. Without a comparison group, there is no way to know how much change would have happened anyway.
• Selection. Sellers and clinics post their best results, and people with no change rarely post at all.
• Unverified product. The vial in the photo has not been tested, so even the ingredients are uncertain.

The GHK-Cu laser trial shows the problem in miniature. Every patient in both groups had significant improvement in wrinkles and skin quality over 12 weeks, because they were healing from a laser treatment. [3] Photographed alone, either group would look like a success story. Only the comparison revealed that the copper peptide made no objective difference. [3]

A 2026 sports medicine review also names the placebo effect as a driver of perceived peptide results and notes that social media amplifies it. [15] Federal Trade Commission guides treat a testimonial about a consumer's results as a claim that those results are typical, which the advertiser must be able to support. [17] For how measured results compare with marketing photos across many peptides, see peptide before and after.

What side effects of GLOW are documented?

No study has recorded side effects of GLOW. What exists is a patchwork for each ingredient, and most of it is an absence of data.

GHK-Cu. Topical GHK-Cu was generally well tolerated in cosmetic studies, with occasional irritation or contact sensitivity reported. [2] There are no systematic human safety data for injected GHK-Cu. Reviews report both pro-repair activity and anti-cancer activity in cell studies, so its effect on an existing tumor is unresolved. [2]

BPC-157. A 2025 systematic review found no clinical safety data in humans and warned that adverse effects are possible from unregulated manufacturing and contamination. [7] A two-person intravenous pilot without a control group reported no side effects and no changes in heart, liver, kidney, thyroid, or glucose markers over three days. [9] In cell and animal studies, BPC-157 promotes new blood vessel growth through the VEGFR2 receptor, which is why reviews raise a theoretical concern about existing tumors. [10]

TB-500. FDA found no report of TB-500 being given to humans and no animal toxicity studies, and it raised a concern that compounded TB-500 may provoke immune reactions because of aggregation and peptide related impurities. [16] Data for full-length thymosin beta-4, a different substance, are reassuring in short trials: intravenous studies in healthy volunteers reported infrequent, mild to moderate adverse events and no serious ones, and topical gel for venous ulcers had safety comparable to placebo. [11] [12] [13] Higher thymosin beta-4 levels in tumors have been associated with invasion and metastasis in colorectal cancer, which is not proof that taking either peptide causes cancer. [14]

The blend. The problems most often reported with injected peptides are injection site pain, redness, and irritation, and rigorous human safety data for unapproved peptides are scarce. [15] Mixing three peptides in one vial adds questions no one has studied: whether they stay stable together, whether they interact, and whether their risks add up.

Is GLOW legal?

There is no federal basis to compound GLOW. A 503A pharmacy may compound from a bulk drug substance only if it has a USP or NF monograph, is a component of an FDA approved drug, or appears on the 503A bulks list. [18] Injectable GHK-Cu meets none of those conditions: its nomination was withdrawn, it is not on the bulks list, and it was not reviewed by the Pharmacy Compounding Advisory Committee in July 2026. [18] A mix is only as eligible as its least eligible ingredient. Track it on the GHK-Cu regulatory page.

BPC-157 and TB-500 are withdrawn nominations and are not on the 503A bulks list either. After the July 2026 advisory committee meeting, news reports said the committee voted to recommend listing them, but FDA's own briefing recommended against listing, and FDA has not posted the vote or minutes. [19] FDA has proposed no rule, and a GLOW-style mix would still contain injectable GHK-Cu.

Products labeled research use only are unapproved new drugs when sold for human use. [21] Topical GHK-Cu is different: cosmetic creams and serums are lawfully sold without FDA premarket approval as long as they make no drug claims, and that is also the form with the human skin data. [20] State compounding and telehealth rules are on our state law pages.

For tested athletes, BPC-157 falls under WADA section S0 and TB-500 under section S2, so a product containing them is prohibited. [22]

What would a real GLOW before and after look like?

A fair test would randomize people to GLOW, to topical GHK-Cu, and to a placebo, photograph everyone under the same standardized lighting, and have evaluators who do not know who got what rate wrinkles, elasticity, and side effects at the same time points. No such trial has been registered or published. Until one exists, reported GLOW results are anecdotes, and the honest summary is that the blend's skin story is borrowed from topical creams and its healing story from rodents. [1] [7]

The takeaway

GLOW has no measured before and after. Its best human evidence is topical GHK-Cu on skin, which is small, partly negative in its one randomized trial, and does not involve injection. Its side effects in people are undocumented, and it has no federal basis to be compounded. If your goal is skin or hair, a dermatologist can discuss treatments with trial evidence. We will update this page if a study of GLOW is published or FDA changes the status of any ingredient.